Detection of SARS-CoV-2 RNA by direct RT-qPCR on nasopharyngeal specimens without

extraction of viral RNA

Mohammad Rubayet Hasan[1,2], Faheem Mirza[1], Hamad Al-Hail[1], Sathyavathi Sundararaju[1],

Thabisile Xaba[1], Muhammad Iqbal[1], Hashim Alhussain[3], Hadi Mohamad Yassine[3], Andres Perez

Lopez[1,2], Patrick Tang[1,2]

[1]Department of Pathology, Sidra Medicine; [2]Weill Cornell Medical College in Qatar, Doha, Qatar;

[3]Qatar University, Doha, Qatar

Short title: SARS-CoV-2 detection by RT-qPCR without RNA extraction

Corresponding author:

Mohammad Rubayet Hasan, PhD, FCCM, D(ABMM)

Clinical Molecular Microbiologist, Department of Pathology

Assistant Professor of Clinical Pathology and Laboratory Medicine

Weill Cornell Medical College in Qatar (WCMC-Q)

Sidra Medicine

Office no: H2M-24093

PO Box 26999, Doha, Qatar

Direct: +974 4003 2996

Mobile: +974 3003 5501

mhasan@sidra.org / http://www.sidra.org/doctors/mohammad-rubayet-hasan/

Abstract

To circumvent the limited availability of RNA extraction reagents, we aimed to develop a

protocol for direct RT-qPCR to detect SARS-CoV-2 in nasopharyngeal swabs without RNA

extraction. Nasopharyngeal specimens positive for SARS-CoV-2 and other coronaviruses

collected in universal viral transport (UVT) medium were pre-processed by several commercial

and laboratory-developed methods and tested by RT-qPCR assays without RNA extraction using

different RT-qPCR master mixes. The results were compared to that of standard approach that

involves RNA extraction. Incubation of specimens at 65°C for 10 minutes along with the use of

TaqPath™ 1-Step RT-qPCR Master Mix provides higher analytical sensitivity for detection of

SARS-CoV-2 RNA than many other conditions tested. The optimized direct RT-qPCR approach

demonstrated a limit of detection of 6.6×10^3 copy/ml and high reproducibility (co-efficient of

variation = 1.2%). In 132 nasopharyngeal specimens submitted for SARS-CoV-2 testing, the

sensitivity, specificity and accuracy of our optimized approach were 95%, 99% and 98.5%,

respectively, with reference to the standard approach. Also, the RT-qPCR C_T values obtained by

the two methods were positively correlated (Pearson correlation coefficient r=0.6971, p=0.0013).

The rate of PCR inhibition by the direct approach was 8% compared to 9% by the standard

approach. Our simple approach to detect SARS-CoV-2 RNA by direct RT-qPCR may help

laboratories continue testing for the virus despite reagent shortages or expand their testing

capacity in resource limited settings.

Introduction

The ongoing pandemic of coronavirus disease (COVID-19) caused by a novel

coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) posed an

unprecedented public health threat to the entire world. In the absence of an effective vaccine or

specific treatment against the virus, early detection and contact tracing, physical distancing

measures and quarantine of cases are considered the cornerstones to curb the community

transmission of SARS-CoV-2 [1-3]. Since the virus was identified and its genome sequenced in

early January 2020, detection of viral RNA in respiratory specimens by real-time reverse

transcription PCR (RT-qPCR) remains the main approach to manage the outbreak by allowing

early detection of cases and targeted measures to prevent transmission of the virus [4]. The

massive demand for SARS-CoV-2 RT-qPCR has brought about a global shortage and supply

chain irregularities of RNA extraction kits that are crucial for RT-qPCR testing [5-7]. In this

study, we tested a number of commercial and laboratory-developed, specimen pre-treatment

procedures to optimize the performance of direct RT-qPCR for SARS-CoV-2 avoiding the RNA

extraction step. This method was validated against a standard approach that included extraction

of viral RNA on a commercial automated extraction platform.

Materials and methods

Standard approach for detection of SARS-CoV-2 RNA from nasopharyngeal specimens

in our laboratory involves extraction of total nucleic acids from specimens in an IVD-labeled,

automated extraction platform followed by RT-qPCR, based on one of the assays (Table 1)

suggested by World Health Organization (WHO)[8]. The performance standards of the assay

were established in our laboratory according to College of American Pathologists (CAP)

standards, and at time of writing this paper, the assay was used to test more than 2000 respiratory

specimens to screen patients for potential infection with SARS-CoV-2. Therefore, the assay was

used as the reference method for all other alternative approaches assessed in this study. All

specimen preparations, pre-treatments and PCR setup were performed in a Class II Biosafety

cabinet in a Biosafety level 2 (BSL2) facility.

Clinical specimens: Nasopharyngeal flocked swab (NPFS) specimens collected in

universal viral transport (UVT) medium (Becton, Dickinson and Company) (n= 150) submitted

for testing SARS-CoV-2 or other respiratory viruses at Sidra Medicine, Doha, Qatar were used in

this study. To maintain patient anonymity, each sample was coded, and all patient identifiers

were removed to ensure that personnel involved in this study were unaware of any patient

information. Ethics approval was not sought because the study involves laboratory validation of

test methods and the secondary use of anonymous pathological specimens that falls under the

category 'exempted' by Sidra Medicine Institutional Review Board. For spiking experiments,

NPFS specimens (n=6) were collected from laboratory volunteers after obtaining written

informed consents. No personal data were collected, and specimens were labeled with random

numbers so that test results cannot be linked to an individual.

Nucleic acid extraction: Nucleic acids from 0.2 ml of NPFS specimens were extracted on

a NucliSENS® easyMAG platform (bioMérieux, France) according to the methods described by

the manufacturers.

Pre-treatment of specimens: Unless otherwise stated, specimens were diluted using

nuclease free water. Heat treatment of specimens at different temperature was performed in a

ThermoMixer (Eppendorf). Specimens processed with Arcis Coronavirus RNA extraction

research kit (Arcis Biotechnology) were performed according to manufacturer's instructions.

Briefly, 90 µl specimen was mixed with 6 µl Reagent 1 RTU and either left unheated or heat

lysed at 60°C for 5 minutes. 40 µl of lysate was then mixed with 2 µl of Reagent 2a and was used

directly for Rt-qPCR. For Takara PrimeDirect™ Probe RT-qPCR Mix (Takara Bio), 0.2 ml

specimens were heated at 99°C for 10 mins and then centrifuged at 4000rpm for 5 min. The

supernatants were collected and 7µl of supernatant was directly used in RT-qPCR reaction

mixture.

RT-qPCR: Primers and probes for detection of SARS-CoV-2, HCoV-HKU1 and MS2

bacteriophage are listed in Table S1 [4,9,10]. For detection of HCoV-HKU1 using Quantifast

Pathogen RT-PCR + IC kit (Qiagen), five µl of extracted or pre-treated samples were mixed with

20 µl of a master mix containing 5 µl of Quantifast Pathogen RT-PCR + IC Master Mix, 0.25 µl

of Quantfast RT Mix and 0.5 µl of 50 x ROX dye solution and primers and probes to final

concentrations shown in Table S1. Thermal cycling was performed in a ABI7500 Fast instrument

(Thermofisher Scientific) with 1 cycle of reverse transcription at 50°C for 20 min followed by 1

cycle of PCR activation at 95°C for 5 min, followed by 40 amplification cycles each consisting

of 95°C-15s and 60°C-60s. For detection of HCoV-HKU1 using TaqPath™ 1-Step RT-qPCR kit

(Thermofisher Scientific), five µl of extracted or pre-treated samples were mixed with 5 µl of a

master mix containing 5 µl of TaqPath™ 1-Step RT-qPCR Master Mix and primers and probes

to final concentrations shown in Table S1. Thermal cycling was performed in a ABI7500 Fast

instrument (Thermofisher Scientific) with 1 cycle of reverse transcription at 50°C for 15 min

followed by 1 cycle of polymerase activation at 95°C for 2 min, followed by 40 amplification

cycles each consisting of 95°C-15s and 60°C-60s.

For detection of SARS-CoV-2 with standard method, five µl of nucleic acid extracts from

NucliSENS® easyMAG system were mixed with 7.5 µl of a master mix containing 2.5 µl of

Quantifast Pathogen RT-PCR + IC Master Mix, 0.125 µl of Quantfast RT Mix and 0.25 µl of 50

X ROX dye solution and primers and probes to final concentrations shown in Table S1. RNA

extraction and PCR inhibition were monitored by an internal control PCR assay, using the

primers and probes shown in Table S1. Specimens were spiked with a tittered preparation of

MS2 bacteriophage to serve as a template for internal control assay. For direct PCR on

specimens, pre-treated specimens were assessed in the same way except that extracted MS2

bacteriophage RNA was mixed with PCR master mix to serve as an inhibition control. A

synthetic RNA (IDT) based on E-Sarbeco assay [4] amplicon sequence was used as a positive

control. As negative control, 0.2 ml neonatal calf serum (NCS) (Thermofisher Scientific) was

extracted along with specimens and used with each PCR run. SARS-CoV-2 RT-qPCR with

Takara PrimeDirect™ Probe RT-qPCR Mix was performed as described by the manufacturer.

Briefly, 7 µl of processed samples were mixed with 18 µl of master mix containing 12.5 µl of

PrimeDirect Probe RT-qPCR Mix and primers and probes to final concentrations shown in Table

1. Thermal cycling was performed in a ABI7500 Fast instrument (Thermofisher Scientific) with

1 cycle of denaturation at 96°C for 10 sec, 1 cycle of reverse transcription at 60°C for 5 min

followed by 45 amplification cycles each consisting of 95°C-5s and 60°C-30s. SARS-CoV-2

RT-qPCR with TaqPath™ 1-Step RT-qPCR kit with the optimized approach (specimens heat

treated at 65°C for 10 min) was performed as above except that 8 µl of specimen was used per 20

µl reaction.

A total of 132 NPS that were previously tested by the standard approach were also tested

by the optimized, direct approach and the results were compared. In addition, an external quality

assessment (EQA) panel (8 specimens) from Quality Control for Molecular Diagnostics

(QCMD) was tested simultaneously with the standard and the direct approach, as well as with a

QIAstat-Dx Respiratory 2019-nCoV Panel (Qiagen) and the results were compared with

expected results.

Limit of detection (LOD) study: A SARS-CoV-2 positive nasopharyngeal specimen (C_T

= 23.3) was titered by the optimized approach using synthetic RNA, and serially diluted (up to

5×10^{-7} - fold) using a negative specimen. All diluted specimens were pre-treated by heating at

65°C for 10 min and then assessed by SARS-CoV-2 RT-qPCR in replicates of 8. The C_T values

obtained were used to calculate limit of detection (LOD) and intra-assay reproducibility of direct

RT-qPCR.

Statistical analysis: Sensitivity, defined as the number of true positive results divided by

the sum of true positive and false negative results; specificity, defined as the number of true

negative results divided by the sum of true negative and false positive results; and accuracy

(concordance), defined as the sum of true positive and true negative results divided by the total

number of test samples, were calculated and expressed as percentages. Ninety-five percent

confidence intervals (CI) for sensitivity, specificity and accuracy were calculated by the Clopper-

Pearson interval or exact method using an online, diagnostic test evaluation calculator (MedCalc,

2018). Correlation between the RT-qPCR CT values between standard approach and optimized

direct approach was determined by Pearson's coefficient calculator. The limit of detection with

95% endpoint (C_{95}) was determined by Probit regression analysis [11].

Results

Using a human coronavirus HKU1 (hCoV-HKU1) positive specimen as a surrogate for

SARS-CoV-2, we first assessed whether specimens can be used directly for RT-qPCR after 2-10

fold dilution with nuclease free water (NFW), simple heat treatment (100°C for 5 min) and

centrifugation to remove any insoluble material that may be present in the specimen. The pre-

treated specimens were then assessed in parallel with extracted specimens by a previously

described, laboratory developed RT-qPCR for HCoV-HKU1 (Table S1). A significant loss of

sensitivity was observed with a RT-qPCR ΔC_T ranging from 10-14 (Table S2). To determine

whether any components of UVT medium (Becton, Dickinson and Company) were inhibitory to

RT-qPCR, we collected nasopharyngeal flocked swabs (NPFS) from laboratory volunteers in

NFW along with swabs in UTM. We then spiked a SARS-CoV-2 positive specimen to all

specimens and assessed them by SARS-CoV-2 RT-qPCR. However, no significant improvement

in sensitivity was observed (Table S3).

Similar results were observed when two commercial test kits were used for direct RT-

qPCR: Arcis Coronavirus RNA extraction research kit comes with lysis reagents that can be used

directly in RT-qPCR; and Takara PrimeDirect™ Probe RT-qPCR kit provides a master mix that

is compatible with heat-treated specimen extracts. However, in our evaluation both test kits

failed to demonstrate an acceptable level of sensitivity (Tables S4 and S5). Our attempts to

further optimize the pre-treatment conditions showed modest improvement with a non-ionic

detergent, Tween-20, and further improvement with a heating step at 65°C for 10 min without

centrifugation ($\Delta C_T = 5.2$) (Table S6). We then tested this low heat approach with more SARS-

CoV-2 positive specimens and using 3 different RT-qPCR master mixes. Interestingly, we found

that with TaqPath™ 1-Step RT-qPCR Master Mix, 4/4 positive samples were correctly detected

with a ΔC_T range 0.8 – 3.8 (Table 1). On the other hand, two other master mixes gave higher ΔC_T

and 1/4 positive results were missed by both. Based on these results, the optimal pre-treatment

and reaction conditions for the direct approach were: i) transfer and dilute (4-fold) 10 μl of NPFS

specimen in NFW; ii) incubate at 65°C for 10 min; and iii) test 8 μl of heat lysed specimen in a

20 μl reaction using TaqPath™ 1-Step RT-qPCR Master Mix.

The analytical sensitivity of the direct RT-qPCR assay using specimens prepared in this

manner was determined by serially diluting a specimen positive for SARS-CoV-2 with a

negative specimen as a diluent. The positive specimen was titered based on the C_T value

obtained by the direct approach using a standard curve prepared with SARS-CoV-2 synthetic

RNA. The C_T values were linear ($R^2 = >0.99$) over the range of 10^3 copy/ml to 10^8 copy/ml, the

highest concentration used in this analysis (Fig. 1A and 1B). The 95% limit of detection (LOD;

C_{95}) of the assay with the direct approach was $6.6X10^3$ copy/ml. The C_T variation between RT-

qPCR replicates across different concentration of analytes were <1 with an average coefficient of

variation (CV%) of 1.2%.

A total of 132 NPFS specimens that were previously tested with standard approach

including viral RNA extraction were re-tested with the new direct approach. The direct approach

detected all except one positive case with $C_T>38$. On the other hand, the direct approach detected

($C_T>37$) SARS-CoV-2 in one specimen that was negative by standard approach. Overall

agreement of results between two approaches was >98% (Kappa= 0.939; 95% CI = 0.854 to

1.000). The sensitivity and specificity of the new approach compared to the reference method

were 95% and 99%, respectively (Table 2). The RT-qPCR C_T values for all specimens that were

positive by both methods (n=18) were positively correlated with a Pearson coefficient (R) of

0.6971 ($p<0.01$) (Fig. 2). The rate of PCR inhibition among the specimens that gave negative

RT-qPCR results by the direct approach was 8% compared to 9% by the standard approach.

Finally, the direct approach accurately detected SARS-CoV-2 RNA in all except one specimen in

an external quality assessment (EQA) panel provided by Quality Control for Molecular

Diagnostics (QCMD)(Table S7). The specimen that gave discrepant result was reported as

'borderline' by QCMD, and SARS-CoV-2 RNA was also undetectable in this specimen by

standard approach and by a commercial test, QIAstat-Dx Respiratory 2019-nCoV Panel

(Qiagen).

Discussion

Success in RT-qPCR testing depends on multiple factors. RNA extraction is preferable to

the use of direct specimens because the extraction process concentrates and purifies the RNA

targets and excludes PCR inhibitory substances. The use of pre-treated or untreated specimens

directly in RT-qPCR is challenging because of the presence of inhibitors and RNA loss due to

heating and/or RNases. After many attempts with various pre-treatment agents and conditions,

we have determined an optimal pre-treatment protocol complemented with specific RT-qPCR

reagents, that generates results equivalent to standard methods that involve RNA extraction.

Minimizing RNA loss through the low heat approach, appropriate dilution of inhibitory

substances and the higher sensitivity of TaqPath™ 1-Step RT-qPCR Master Mix may have

played a combinatory role in achieving equivalency of the direct RT-qPCR compared to a

standard approach requiring viral RNA extraction.

In summary, our new approach demonstrated high sensitivity and specificity in the

detection of SARS-CoV-2 RNA, and the rate of RT-qPCR inhibition was similar to that of a

standard approach. By skipping the RNA extraction step, the new approach will also

significantly reduce the cost and improve the turn-around time of the assay. Delayed and

inadequate laboratory testing can significantly hamper efforts to control the pandemic. Our

results will help many labs all over the world who are struggling with a shortage of reagents to

continue testing for SARS-CoV-2. Also, because of a significant reduction in cost, the optimized

direct approach we described, will be useful to resource-limited countries to expand their

capacity for RT-qPCR testing.

Acknowledgement

We are grateful for the efforts of all technologists in the Molecular Infectious Disease Laboratory

at Sidra Medicine.

References

1.　Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et. Al. A Novel Coronavirus from

Patients with Pneumonia in China, N Engl J Med 2019;382(8):727-733.

2.　Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health

Organization declares global emergency: A review of the 2019 novel coronavirus

(COVID-19). Int J Surg 2020;76:71-76.

3.　Steffens I. A hundred days into the coronavirus disease (COVID-19) pandemic,

Eurosurveillance. https://www.eurosurveillance.org/content/10.2807/1560-

7917.ES.2020.25.14.2000550#r8. Accessed 18 April 2020.

4.　Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of

2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020;25(3).

5.　Ranney ML, Griffeth V, Jha AK. Critical Supply Shortages - The Need for Ventilators

and Personal Protective Equipment during the Covid-19 Pandemic. N Engl J Med

2020;doi: 10.1056/NEJMp2006141.

6.   Slabodkin G. FDA chief warns of supply 'pressure' on reagents for coronavirus tests.

https://www.medtechdive.com/news/fda-chief-warns-of-supply-pressure-on-reagents-for-

coronavirus-tests/573999/. Accessed 18 April 2020.

7.   Yan Y, Chang L, Wang L. Laboratory testing of SARS-CoV, MERS-CoV, and SARS-

CoV-2 (2019-nCoV): Current status, challenges, and countermeasures. Rev Med Virol

2020;17:e2106.

8.   World Health Organization (WHO). Coronavirus disease (COVID-19) Pandemic.

Geneva: WHO. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.

Accessed 18 April 2020.

9.   Hasan MR, Al Mana H, Young V, Tang P, Thomas E, Tan R, et al. A novel real-time

PCR assay panel for detection of common respiratory pathogens in a convenient, strip-

tube array format. J Virol Methods 2019;265:42-48.

10.   Dreier J, Stormer M, Kleesiek K. Use of bacteriophage MS2 as an internal control in viral

reverse transcription-PCR assays. J Clin Microbiol 2005;43:4551-7.

11.   Burd EM. Validation of laboratory-developed molecular assays for infectious diseases.

Clin Microbiol Rev 2010;23(3):550-576.

272   Table 1: Direct RT-qPCR on SARS-CoV-2 positive and negative NPFS specimens after heating

273   at 65°C for 10 minutes with different RT-qPCR master mixes

	SARS-CoV-2 C_T			
Sample No.	Standard method	Quantifast Pathogen RT-PCR + IC Master Mix	PrimeDirect™ Probe RT-qPCR Mix	TaqPath™ 1-Step RT-qPCR Master Mix
1	21.5	29.4	24.6	22.8
2	34.5	Undetermined	Undetermined	35.3
3	24.5	30.4	28.7	25.5
4	22	29.9	31.4	25.8
5	Undetermined	Undetermined	Undetermined	Undetermined

NPFS specimens were either subjected to viral RNA extraction by standard method using the

NucliSENS easyMAG automated extraction system (bioMerieux), or diluted 4-fold with NFW

followed by incubation at 65°C for 5 minutes. All samples were tested for SARS-CoV-2 RNA by

standard RT-qPCR using different master mixes in duplicate and mean C_T values were

compared.

Table 2: Performance of optimized direct RT-qPCR approach with reference to standard

approach for detection of SARS-CoV-2 RNA

Statistic	Value	95% CI
Total number of specimens	132	-
True positive	18	-
True negative	112	-
False positive	1	-
False negative	1	-
Sensitivity	95.0%	74% to 99.8%
Specificity	99.0%	95.2% to 99.9%
Accuracy	98.5%	94.6% to 99.8%

Figure legends

Figure 1: Linearity of SARS-CoV-2 RT-qPCR by direct approach. A tittered SARS-CoV-2

positive nasopharyngeal specimen was serially diluted using a negative specimen, pre-heated at

65°C for 10 min and assessed by SARS-CoV-2 RT-qPCR as described in the Supplemental

methods. A) Amplification curves from SARS-CoV-2 RT-qPCR assay on the serially diluted

sample. B) RT-qPCR C_T values were plotted against estimated copy number of SARS-CoV-2

RNA in each dilution. Each data point represents an average of data obtained from 8 replicates.

Figure 2: Correlation of RT=qPCR C_T values obtained by direct versus standard approach.

311   Figure 1

328   Figure 2

Supplemental Tables

Table S1: Primers and probes used in this study

Assay	Target	Name	Sequence (5'- 3')	5'-Label	3'-Label	Final concentration (µM)	Source
HCoV-HKU1	Nucleocapsid gene	HCoV-HKU1-F	GATCCTACTAYTCAAGAAG CTATCCCTACT			0.6	(1)
		HCoV-HKU1-R	ACCTTCCTGAGCCTTCAAC ATAAT			0.3	
		HCoV-HKU1-P	TTTYCGCCTGGTACGATTTT GCCTC	JOE/ZEN	IaBkFQ	0.2	
SARS-CoV-2	E gene	E_Sarbeco_F1	ACAGGTACGTTAATAGTTA ATAGCGT			0.4	(2)
		E_Sarbeco_R2	ATATTGCAGCAGTACGCAC ACA			0.4	
		E_Sarbeco_P1	ACACTAGCCATCCTTACTG CGCTTCG	FAM/ZEN	IaBkFQ	0.2	
	Internal control	MS2-TM3-F	GGCTGCTCGCGGATACCC			0.2	(3)
		MS2-TM3-R	TGAGGGAATGTGGGAACC G			0.2	
		MS2-TM2JOE	ACCTCGGGTTTCCGTCTTG CTCGT	JOE/ZEN	IaBkFQ	0.1	

359 Table S2: Direct RT-qPCR on a nasopharyngeal specimen positive for human coronavirus HKU1 after
360 heat treatment at 100°C for 5 minutes

Sample Name	Sample dilution	Sample processing	HKU1 CoV C_T	
			Quantifast Pathogen RT-PCR + IC Master Mix	TaqPath™ 1-Step RT-qPCR Master Mix
1167-H0	Undiluted	easyMAG extraction	24.6	23.8
1167-H1	Undiluted	Heat treatment	36.4	36.6
1167-H2	2 fold dilution	Heat treatment	34.5	35.7
1167-H3	4 fold dilution	Heat treatment	34.7	35.6
1167-H4	10 fold dilution	Heat treatment	34.1	33.2
1167-H5	Undiluted	Freeze thaw; heat treatment	38.1	36.1

NPFS specimens were either i) subjected to viral RNA extraction by standard method using a NucliSENS
easyMAG automated extraction system (Biomerieux), or ii) serially diluted with nuclease free water
(NFW) followed by incubation at 100°C for 5 minutes, or iii) freeze thawed once prior to heat treatment.
All heat-treated samples were centrifuged at 13,000 rpm for 5 minutes at 4°C and supernatants were
collected. All samples were tested for SARS-CoV-2 RNA by standard RT-qPCR in duplicate and mean
C_T values were compared.

Table S3: Direct RT-qPCR on simulated, dry NPFS using a spiked specimen positive for SARS-CoV-2

Sample No.	SARS-CoV-2 C_T	
	Standard method	Direct PCR on dry NPFS
1	20.8	32.4
2	20.5	25.8
3	20.8	32.4
4	25.7	31.6
5	25.8	33.8
6	25.6	34.5

Specimens were collected from laboratory members who volunteered to provide specimens. NPFS specimens were either i) collected in VTM or ii) collected in sterile empty tubes as dry swabs and later resuspended in 1 ml of NFW. Five μl of a patient specimen positive for SARS-CoV-2 RNA ($C_T = 22$) were spiked into 0.2 ml of specimens collected in VTM of NFW. VTM specimens were extracted by standard method using a NucliSENS easyMag automated extraction system (bioMerieux). Specimens collected in NFW were incubated at 100ºC for 5 minutes and centrifuged at 13,000 rpm for 5 minutes at 4ºC and supernatants were collected. All samples were tested for SARS-CoV-2 RNA by standard RT-qPCR using Quantifast Pathogen RT-PCR + IC Master Mix in duplicate and mean C_T values were compared.

399 Table S4: Direct RT-qPCR on SARS-CoV-2 positive and negative NPFS specimens processed using
400 Arcis Pathogen Kit

Sample No.	SARS-CoV-2 C_T		
	Standard method	Arcis kit with heating	Arcis kit - no heating
1	Undetermined	Undetermined	Undetermined
2	Undetermined	Undetermined	Undetermined
3	Undetermined	Undetermined	Undetermined
4	25.0	34.9	33.5
5	21.0	32.9	Undetermined
6	23.0	28.4	32.3

403 NPFS specimens were processed according to manufacturer's protocol (Arcis Biotechnology Ltd.). All
404 samples were tested for SARS-CoV-2 RNA by standard RT-qPCR in duplicate and mean C_T values were
405 compared.

418   Table S5: Direct RT-qPCR on SARS-CoV-2 positive and negative NPFS specimens processed using
419   Takara

Sample No.	SARS-CoV-2 C_T	
	Standard method	Takara PrimeDirect protocol
1	21.5	29.78692245
2	34.5	Undetermined
3	24.5	Undetermined
4	33.7	Undetermined
5	Undetermined	Undetermined

422   NPFS specimens were processed according to manufacturer's protocol (PrimeDirect™ Probe RT-qPCR
423   Mix, Takara Bio Inc.). All samples were tested for SARS-CoV-2 RNA by standard RT-qPCR in duplicate
424   and mean C_T values were compared.

Table S6: Direct RT-qPCR on SARS-CoV-2 positive and negative NPFS specimens with or without heating at 65°C for 5 minutes or after lysis using a non-ionic detergent

Sample No.	SARS-CoV-2 C_T			
	Standard method	No treatment	Heat treatment	Lysis with 0.2% Tween-20
1	21.5	30.6	26.7	28.4
2	34.5	Undetermined	Undetermined	Undetermined
3	Undetermined	Undetermined	Undetermined	Undetermined
4	Undetermined	Undetermined	Undetermined	Undetermined
5	Undetermined	Undetermined	Undetermined	Undetermined

NPFS specimens were either i) subjected to viral RNA extraction by standard method using a NucliSENS easyMAG automated extraction system (bioMerieux), or ii) diluted 4-fold with nuclease free water (NFW) iii) diluted 4-fold with nuclease free water (NFW) followed by incubation at 65°C for 5 minutes or iv) diluted 4-fold with Tween-20 to final concentration of 0.2% followed by incubation at room temperature for 10 min. All samples were tested for SARS-CoV-2 RNA by standard RT-qPCR using Quantifast Pathogen RT-PCR + IC Master Mix.

461   Table S7: Direct RT-qPCR on QCMD EQA specimens

Sample No.	QCMD result	SARS-CoV-2 C_T		
		Standard approach	QIAstat	Direct approach
Sample 1	Positive	33.4	34	35.5
Sample 2	Negative	undetermined	undetermined	Undetermined
Sample 3	Positive	35.2	35.4	37.1
Sample 4	Negative	undetermined	undetermined	Undetermined
Sample 5	Negative	undetermined	undetermined	Undetermined
Sample 6	Positive	34.2	36.7	35.1
Sample 7	Positive	29.4	31.5	31.7
Sample 8	Borderline	undetermined	undetermined	Undetermined

464   QCMD EQA specimens were simultaneously tested by standard and direct approach and by QIAstat-Dx
465   Respiratory 2019-nCoV Panel (Qiagen)